# A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)

> **NCT07222488** · PHASE1,PHASE2 · RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 45 (estimated)

## Conditions studied

- Bladder Cancer
- Urinary Bladder Neoplasms

## Interventions

- **BIOLOGICAL:** MK-3120

## Key facts

- **NCT ID:** NCT07222488
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-09
- **Primary completion:** 2029-02-28
- **Final completion:** 2029-02-28
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07222488

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07222488, "A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07222488. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*